(Q43267042)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19803960%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19803960%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19803960%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Miguel Martin

series ordinal

1

1 reference

17 November 2017

1 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19803960%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19803960%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19803960%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19803960%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

527-537

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19803960%20AND%20SRC:MED&resulttype=core&format=json

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

9 February 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast canc

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

NSABP breast cancer clinical trials: recent results and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

Expression of FGF-2 alters focal adhesion dynamics in migration-restricted MDA-MB-231 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.4.527

21 January 2018

Identifiers

DOI

10.2217/17455057.2.4.527

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19803960%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference